Published

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: ACS pharmacology & translational science
Date: 2021-04-09
Source: PubMed
DOI: 10.1021/acsptsci.1c00020
PubMed: 33860185

Authors

Ross S Agin-Liebes G Lo S Zeifman RJ Ghazal L Benville J Franco Corso S Bjerre Real C Guss J Bossis A Mennenga SE

Watch author

Derived topics and classifications

psilocybin Depression End-of-Life Distress Clinical Trial Randomized Controlled Trial Safety Randomized Controlled Trial

Citation graph

0 referenced DOIs found in stored source metadata. 7 indexed papers cite this DOI.

Open citation network

Indexed papers citing this DOI

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: The case for a hybrid group-based delivery model2026-12-01 Changes in anxiety, quality of life, and functioning following psilocybin-assisted therapy in veterans with treatment-resistant depression2026-11-01 Learnings from a hybrid communities of practice group therapy model to support psilocybin-assisted therapy for patients with a terminal diagnosis2026-07-20 Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholders2026-07-01 Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations2026-06-01 Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression2026-04-09 Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer.2021-04-09

Related papers

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical TrialClinicalTrials.gov · 2026-07-10 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical TrialClinicalTrials.gov · 2026-07-10 Psychedelics and mental health: reimagining care through science, insight, and compassion.Frontiers in pharmacology · 2025-01-01 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.ClinicalTrials.gov · 2026-05-08 Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.Palliative & supportive care · 2023-08-01 Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label TrialClinicalTrials.gov · 2026-06-23 Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)ClinicalTrials.gov · 2026-04-29 Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy VolunteersClinicalTrials.gov · 2026-02-05